GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cochlear Ltd (OTCPK:CHEOY) » Definitions » Loans Receivable

CHEOY (Cochlear) Loans Receivable : $0 Mil (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Cochlear Loans Receivable?

Cochlear's Loans Receivable for the quarter that ended in Jun. 2024 was $0 Mil.


Cochlear Loans Receivable Historical Data

The historical data trend for Cochlear's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cochlear Loans Receivable Chart

Cochlear Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cochlear Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cochlear Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Cochlear Loans Receivable Related Terms

Thank you for viewing the detailed overview of Cochlear's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Cochlear Business Description

Traded in Other Exchanges
Address
1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.